

# Immune Checkpoint Inhibitors Market by Type (CTLA-4 Inhibitor, PD-1 Inhibitor, and PD-L1 Inhibitor) and Application (Lung Cancer, Bladder Cancer, Melanoma, Hodgkin Lymphoma, and Others) - Global Opportunity Analysis and Industry Forecast, 2018-2025

<https://marketpublishers.com/r/IAAB2F7AD7AEN.html>

Date: September 2018

Pages: 149

Price: US\$ 5,370.00 (Single User License)

ID: IAAB2F7AD7AEN

## Abstracts

The global immune checkpoint inhibitors market was valued at \$10,540 million in 2017, and is projected to reach \$65,427 million by 2025, registering a CAGR of 25.6% from 2018 to 2025.

Checkpoint inhibitor is a type of drug used in immunotherapy, which helps block the proteins present on tumor cells, as these affect the functioning of the immune system. Immune checkpoint inhibitor drugs block different checkpoint proteins, including cytotoxic T lymphocyte associated protein 4 (CTLA-4), programmed cell death protein (PD-1), and programmed death ligand 1 (PD-L1). Immune checkpoint inhibitors have witnessed increasing demand, owing to increase in incidence of different forms of cancer, surge in awareness of checkpoint inhibitors for the treatment of cancer, higher number of pipeline drugs, and upsurge in adoption of immune checkpoint inhibitor drugs. In addition, growth in the geriatric population and technological advancements in screening & diagnosis of cancer drive the market growth. However, high cost associated with immune checkpoint inhibitors is projected to impede the market growth.

The global immune checkpoint inhibitor market is segmented based on type, application, and region. On the basis of type, the market is classified as CTLA-4 inhibitor, PD-1 inhibitor, and PD-L1 inhibitor. The applications covered in the study include lung cancer, bladder cancer, melanoma, Hodgkin lymphoma, and others.

Region wise, the market is studied across North America (U.S., Canada, and Mexico), Europe (Germany, France, the UK, and rest of Europe), Asia-Pacific (China, Japan, Australia, India, and rest of Asia-Pacific), and LAMEA (Brazil and rest of LAMEA).

## **KEY BENEFITS FOR STAKEHOLDERS**

The study provides an in-depth analysis of the market along with the current trends and future estimations to elucidate the imminent investment pockets.

It offers a quantitative analysis from 2017 to 2025, which is expected to enable the stakeholders to capitalize on the prevailing market opportunities.

A comprehensive analysis of all the geographical regions is provided to determine the existing opportunities.

The profiles and growth strategies of the key players are thoroughly analyzed to understand the competitive outlook of the global market.

## **KEY MARKET SEGMENTS**

### By Type

CTLA-4 Inhibitor

PD-1 Inhibitor

PD-L1 Inhibitor

### By Application

Lung Cancer

Bladder Cancer

Melanoma

Hodgkin Lymphoma

Others

## By Region

North America

U.S.

Canada

Mexico

Europe

Germany

France

UK

Rest of Europe

Asia-Pacific

Japan

China

Australia

India

Rest of Asia-Pacific

LAMEA

Brazil

Rest of LAMEA

## LIST OF KEY PLAYERS PROFILED IN THE REPORT

AstraZeneca PLC

Bristol-Myers Squibb Company

Eli Lilly and Company (ARMO Biosciences)

Fortress Biotech, Inc. (Checkpoint Therapeutics, Inc.)

F. Hoffmann-La Roche Ltd. (Genentech, Inc.)

Immutep Limited

Merck & Co., Inc.

Merck KGaA (EMD Serono, Inc.)

Novartis AG

Pfizer Inc.

LIST OF OTHER PLAYERS IN THE VALUE CHAIN (These players are not profiled in the report. The same will be included on request.)

Incyte Corporation

NewLink Genetics

## Contents

### CHAPTER 1: INTRODUCTION

- 1.1. Report description
- 1.2. Key benefits for stakeholders
- 1.3. Key market segments
  - 1.3.1. List of key players profiled in the report
- 1.4. Research methodology
  - 1.4.1. Secondary research
  - 1.4.2. Primary research
  - 1.4.3. Analyst tools and models

### CHAPTER 2: EXECUTIVE SUMMARY

- 2.1. Key findings of the study
  - 2.1.1. CXO perspective

### CHAPTER 3: MARKET OVERVIEW

- 3.1. Market definition and scope
- 3.2. Key findings
  - 3.2.1. Top investment pockets
  - 3.2.2. Top player positioning
- 3.3. MARKET DYNAMICS
  - 3.3.1. Drivers
    - 3.3.1.1. Increase in incidence of cancer across the globe
    - 3.3.1.2. Surge in global geriatric population
    - 3.3.1.3. Supportive reimbursement policies for immune checkpoint inhibitors
    - 3.3.1.4. Surge in healthcare expenditure worldwide
  - 3.3.2. Restraint
    - 3.3.2.1. Higher cost of immune checkpoint inhibitors
  - 3.3.3. Opportunities
    - 3.3.3.1. Increase in number of pipeline drugs
    - 3.3.3.2. Growth opportunities in the emerging markets
  - 3.3.4. Impact analyses
- 3.4. Clinical trials
- 3.5. Pipeline analyses

## **CHAPTER 4: IMMUNE CHECKPOINT INHIBITORS MARKET, BY TYPE**

### 4.1. Overview

#### 4.1.1. Market size and forecast

### 4.2. CTLA-4 inhibitor

#### 4.2.1. Key market trends, growth factors, and opportunities

#### 4.2.2. Market size and forecast

### 4.3. PD-1 inhibitor

#### 4.3.1. Key market trends, growth factors, and opportunities

#### 4.3.2. Market size and forecast

### 4.4. PD-L1 inhibitor

#### 4.4.1. Key market trends, growth factors, and opportunities

#### 4.4.2. Market size and forecast

## **CHAPTER 5: IMMUNE CHECKPOINT INHIBITORS MARKET, BY APPLICATION**

### 5.1. Overview

#### 5.1.1. Market size and forecast

### 5.2. Lung cancer

#### 5.2.1. Market size and forecast

### 5.3. Bladder cancer

#### 5.3.1. Market size and forecast

### 5.4. Melanoma

#### 5.4.1. Market size and forecast

### 5.5. Hodgkin lymphoma

#### 5.5.1. Market size and forecast

### 5.6. Others

#### 5.6.1. Market size and forecast

## **CHAPTER 6: IMMUNE CHECKPOINT INHIBITORS MARKET, BY REGION**

### 6.1. Overview

#### 6.1.1. Market size and forecast

### 6.2. North America

#### 6.2.1. Key market trends, growth factors, and opportunities

#### 6.2.2. North America market size and forecast, by country

##### 6.2.2.1. U.S.

##### 6.2.2.2. Canada

##### 6.2.2.3. Mexico

- 6.2.3. North America market size and forecast, by type
- 6.2.4. North America market size and forecast, by application
- 6.3. Europe
  - 6.3.1. Key market trends, growth factors, and opportunities
  - 6.3.2. Europe market size and forecast, by country
    - 6.3.2.1. Germany
    - 6.3.2.2. France
    - 6.3.2.3. UK
    - 6.3.2.4. Rest of Europe
  - 6.3.3. Europe market size and forecast, by type
  - 6.3.4. Europe market size and forecast, by application
- 6.4. Asia-Pacific
  - 6.4.1. Key market trends, growth factors, and opportunities
  - 6.4.2. Asia-Pacific market size and forecast, by country
    - 6.4.2.1. Japan
    - 6.4.2.2. China
    - 6.4.2.3. Australia
    - 6.4.2.4. India
    - 6.4.2.5. Rest of Asia-Pacific
  - 6.4.3. Asia-Pacific market size and forecast, by type
  - 6.4.4. Asia-Pacific market size and forecast, by application
- 6.5. LAMEA
  - 6.5.1. Key market trends, growth factors, and opportunities
  - 6.5.2. LAMEA market size and forecast, by country
    - 6.5.2.1. Brazil
    - 6.5.2.2. Rest of LAMEA
  - 6.5.3. LAMEA market size and forecast, by type
  - 6.5.4. LAMEA market size and forecast, by application

## **CHAPTER 7: COMPANY PROFILES**

- 7.1. AstraZeneca Plc.
  - 7.1.1. Company overview
  - 7.1.2. Company snapshot
  - 7.1.3. Operating business segments
  - 7.1.4. Product Portfolio
  - 7.1.5. Business performance
  - 7.1.6. Key strategic moves and developments
- 7.2. Bristol-Myers Squibb Company

- 7.2.1. Company overview
- 7.2.2. Company snapshot
- 7.2.3. Operating business segments
- 7.2.4. Product portfolio
- 7.2.5. Business performance
- 7.2.6. Key strategic moves and developments
- 7.3. Eli Lilly and Company (ARMO BioSciences)
  - 7.3.1. Company overview
  - 7.3.2. Company snapshot
  - 7.3.3. Operating business segments
  - 7.3.4. Product Portfolio
  - 7.3.5. Business performance
- 7.4. Fortress Biotech, Inc. (Checkpoint Therapeutics, Inc.)
  - 7.4.1. Company overview
  - 7.4.2. Company snapshot
  - 7.4.3. Operating business segments
  - 7.4.4. Product portfolio
  - 7.4.5. Business performance
- 7.5. F. Hoffmann-La Roche Ltd. (Genentech, Inc.)
  - 7.5.1. Company overview
  - 7.5.2. Company snapshot
  - 7.5.3. Operating business segments
  - 7.5.4. Product portfolio
  - 7.5.5. Business performance
  - 7.5.6. Key strategic moves and developments
- 7.6. Immuteq Limited
  - 7.6.1. Company overview
  - 7.6.2. Company snapshot
  - 7.6.3. Operating business segments
  - 7.6.4. Product Portfolio
  - 7.6.5. Business performance
- 7.7. Merck & Co., Inc.
  - 7.7.1. Company overview
  - 7.7.2. Company snapshot
  - 7.7.3. Operating business segments
  - 7.7.4. Product Portfolio
  - 7.7.5. Business performance
  - 7.7.6. Key strategic moves and developments
- 7.8. Merck KGaA (EMD Serono, Inc.)



- 7.8.1. Company overview
- 7.8.2. Company snapshot
- 7.8.3. Operating business segments
- 7.8.4. Product Portfolio
- 7.8.5. Business performance
- 7.8.6. Key strategic moves and developments
- 7.9. Novartis AG
  - 7.9.1. Company overview
  - 7.9.2. Company snapshot
  - 7.9.3. Operating business segments
  - 7.9.4. Product Portfolio
  - 7.9.5. Business performance
- 7.10. Pfizer Inc.
  - 7.10.1. Company overview
  - 7.10.2. Company snapshot
  - 7.10.3. Operating business segments
  - 7.10.4. Product Portfolio
  - 7.10.5. Business performance
  - 7.10.6 Key strategic moves and development

## List Of Tables

### LIST OF TABLES

TABLE 01. CLINICAL TRIALS IN IMMUNE CHECKPOINT INHIBITORS MARKET, 2015-2018

TABLE 02. PRODUCT PIPELINE ANALYSIS (PHASE II & III)

TABLE 03. GLOBAL IMMUNE CHECKPOINT INHIBITORS MARKET, BY TYPE, 2017-2025 (\$MILLION)

TABLE 04. CTLA-4 INHIBITOR MARKET, BY REGION, 2017-2025 (\$MILLION)

TABLE 05. PD-1 INHIBITOR MARKET, BY REGION, 2017-2025 (\$MILLION)

TABLE 06. PD-L1 INHIBITOR MARKET, BY REGION, 2017-2025 (\$MILLION)

TABLE 07. GLOBAL IMMUNE CHECKPOINT INHIBITORS MARKET, BY APPLICATION, 2017-2025 (\$MILLION)

TABLE 08. LUNG CANCER IMMUNE CHECKPOINT INHIBITORS MARKET, BY REGION, 2017-2025 (\$MILLION)

TABLE 09. BLADDER CANCER IMMUNE CHECKPOINT INHIBITORS MARKET, BY REGION, 2017-2025 (\$MILLION)

TABLE 10. MELANOMA IMMUNE CHECKPOINT INHIBITORS MARKET, BY REGION, 2017-2025 (\$MILLION)

TABLE 11. HODGKIN LYMPHOMA IMMUNE CHECKPOINT INHIBITORS MARKET, BY REGION, 2017-2025 (\$MILLION)

TABLE 12. OTHERS IMMUNE CHECKPOINT INHIBITORS MARKET, BY REGION, 2017-2025 (\$MILLION)

TABLE 13. IMMUNE CHECKPOINT INHIBITORS MARKET REVENUE, BY REGION, 2017-2025 (\$MILLION)

TABLE 14. NORTH AMERICA IMMUNE CHECKPOINT INHIBITORS MARKET, BY COUNTRY, 2017-2025 (\$MILLION)

TABLE 15. NORTH AMERICA IMMUNE CHECKPOINT INHIBITORS MARKET, BY TYPE, 2017-2025 (\$MILLION)

TABLE 16. NORTH AMERICA IMMUNE CHECKPOINT INHIBITORS MARKET, BY APPLICATION, 2017-2025 (\$MILLION)

TABLE 17. EUROPE IMMUNE CHECKPOINT INHIBITORS MARKET, BY COUNTRY, 2017-2025 (\$MILLION)

TABLE 18. EUROPE IMMUNE CHECKPOINT INHIBITORS MARKET, BY TYPE, 2017-2025 (\$MILLION)

TABLE 19. EUROPE IMMUNE CHECKPOINT INHIBITORS MARKET, BY APPLICATION, 2017-2025 (\$MILLION)

TABLE 20. ASIA-PACIFIC IMMUNE CHECKPOINT INHIBITORS MARKET, BY

COUNTRY, 2017-2025 (\$MILLION)

TABLE 21. ASIA-PACIFIC IMMUNE CHECKPOINT INHIBITORS MARKET, BY TYPE, 2017-2025 (\$MILLION)

TABLE 22. ASIA-PACIFIC IMMUNE CHECKPOINT INHIBITORS MARKET, BY APPLICATION, 2017-2025 (\$MILLION)

TABLE 23. LAMEA IMMUNE CHECKPOINT INHIBITORS MARKET, BY COUNTRY, 2017-2025 (\$MILLION)

TABLE 24. LAMEA IMMUNE CHECKPOINT INHIBITORS MARKET, BY TYPE, 2017-2025 (\$MILLION)

TABLE 25. LAMEA IMMUNE CHECKPOINT INHIBITORS MARKET, BY APPLICATION, 2017-2025 (\$MILLION)

TABLE 26. ASTRAZENECA: COMPANY SNAPSHOT

TABLE 27. ASTRAZENECA: OPERATING SEGMENTS

TABLE 28. ASTRAZENECA: PRODUCT PORTFOLIO

TABLE 29. BRISTOL-MYERS SQUIBB: COMPANY SNAPSHOT

TABLE 30. BRISTOL-MYERS SQUIBB: PRODUCT PORTFOLIO

TABLE 31. LILLY: COMPANY SNAPSHOT

TABLE 32. LILLY: OPERATING SEGMENTS

TABLE 33. LILLY: PRODUCT PORTFOLIO

TABLE 34. FORTRESS: COMPANY SNAPSHOT

TABLE 35. FORTRESS: OPERATING SEGMENTS

TABLE 36. FORTRESS: PRODUCT PORTFOLIO

TABLE 37. ROCHE: COMPANY SNAPSHOT

TABLE 38. ROCHE: OPERATING SEGMENTS

TABLE 39. ROCHE: PRODUCT PORTFOLIO

TABLE 40. IMMUTEP: COMPANY SNAPSHOT

TABLE 41. IMMUTEP: PRODUCT PORTFOLIO

TABLE 42. MERCK: COMPANY SNAPSHOT

TABLE 43. MERCK: OPERATING SEGMENTS

TABLE 44. MERCK: PRODUCT PORTFOLIO

TABLE 45. MERCK: COMPANY SNAPSHOT

TABLE 46. MERCK: OPERATING SEGMENTS

TABLE 47. MERCK: PRODUCT PORTFOLIO

TABLE 48. NOVARTIS: COMPANY SNAPSHOT

TABLE 49. NOVARTIS: OPERATING SEGMENTS

TABLE 50. NOVARTIS: PRODUCT PORTFOLIO

TABLE 51. PFIZER: COMPANY SNAPSHOT

TABLE 52. PFIZER: OPERATING SEGMENTS

TABLE 53. PFIZER: PRODUCT PORTFOLIO



## List Of Figures

### LIST OF FIGURES

- FIGURE 01. IMMUNE CHECKPOINT INHIBITORS MARKET SEGMENTATION
- FIGURE 02. TOP INVESTMENT POCKETS
- FIGURE 03. TOP PLAYER POSITIONING, 2017
- FIGURE 04. WORLD POPULATION AGED 65 AND OVER (%)
- FIGURE 05. IMPACT ANALYSES
- FIGURE 06. U.S. IMMUNE CHECKPOINT INHIBITORS MARKET, 2017-2025 (\$MILLION)
- FIGURE 07. CANADA IMMUNE CHECKPOINT INHIBITORS MARKET, 2017-2025 (\$MILLION)
- FIGURE 08. MEXICO IMMUNE CHECKPOINT INHIBITORS MARKET, 2017-2025 (\$MILLION)
- FIGURE 09. GERMANY IMMUNE CHECKPOINT INHIBITORS MARKET, 2017-2025 (\$MILLION)
- FIGURE 10. FRANCE IMMUNE CHECKPOINT INHIBITORS MARKET, 2017-2025 (\$MILLION)
- FIGURE 11. UK IMMUNE CHECKPOINT INHIBITORS MARKET, 2017-2025 (\$MILLION)
- FIGURE 12. REST OF EUROPE IMMUNE CHECKPOINT INHIBITORS MARKET, 2017-2025 (\$MILLION)
- FIGURE 13. JAPAN IMMUNE CHECKPOINT INHIBITORS MARKET, 2017-2025 (\$MILLION)
- FIGURE 14. CHINA IMMUNE CHECKPOINT INHIBITORS MARKET, 2017-2025 (\$MILLION)
- FIGURE 15. AUSTRALIA IMMUNE CHECKPOINT INHIBITORS MARKET, 2017-2025 (\$MILLION)
- FIGURE 16. INDIA IMMUNE CHECKPOINT INHIBITORS MARKET, 2017-2025 (\$MILLION)
- FIGURE 17. REST OF ASIA-PACIFIC IMMUNE CHECKPOINT INHIBITORS MARKET, 2017-2025 (\$MILLION)
- FIGURE 18. BRAZIL IMMUNE CHECKPOINT INHIBITORS MARKET, 2017-2025 (\$MILLION)
- FIGURE 19. REST OF LAMEA IMMUNE CHECKPOINT INHIBITORS MARKET, 2017-2025 (\$MILLION)
- FIGURE 20. ASTRAZENECA: REVENUE, 2015-2017 (\$MILLION)
- FIGURE 21. ASTRAZENECA: REVENUE SHARE BY GEOGRAPHY, 2017 (%)

- FIGURE 22. REVENUE, 2015-2017 (\$MILLION)
- FIGURE 23. BRISTOL-MYERS SQUIBB: REVENUE SHARE BY REGION, 2017 (%)
- FIGURE 24. REVENUE, 2015-2017 (\$MILLION)
- FIGURE 25. LILLY: REVENUE SHARE BY SEGMENT, 2017 (%)
- FIGURE 26. LILLY: REVENUE SHARE BY REGION, 2017 (%)
- FIGURE 27. FORTRESS: NET SALES, 2015-2017 (\$MILLION)
- FIGURE 28. FORTRESS: REVENUE SHARE BY SEGMENT, 2017 (%)
- FIGURE 29. ROCHE: NET SALES, 2015-2017 (\$MILLION)
- FIGURE 30. ROCHE: REVENUE SHARE BY SEGMENT, 2017 (%)
- FIGURE 31. ROCHE: REVENUE SHARE BY GEOGRAPHY, 2017 (%)
- FIGURE 32. IMMUTEP: NET SALES, 2015-2017 (\$MILLION)
- FIGURE 33. MERCK: NET SALES, 2015-2017 (\$MILLION)
- FIGURE 34. MERCK: NET SALES BY SEGMENT, 2017 (%)
- FIGURE 35. MERCK: NET SALES BY GEOGRAPHY, 2017 (%)
- FIGURE 36. MERCK: NET SALES, 2015-2017 (\$MILLION)
- FIGURE 37. MERCK: REVENUE SHARE BY SEGMENT, 2017 (%)
- FIGURE 38. MERCK: REVENUE SHARE BY GEOGRAPHY, 2017 (%)
- FIGURE 39. NET SALES, 2015-2017 (\$MILLION)
- FIGURE 40. NOVARTIS: REVENUE SHARE BY SEGMENT, 2017 (%)
- FIGURE 41. NOVARTIS: REVENUE SHARE BY GEOGRAPHY, 2017 (%)
- FIGURE 42. PFIZER: REVENUE, 2015-2017 (\$MILLION)
- FIGURE 43. PFIZER: REVENUE SHARE BY SEGMENT, 2017 (%)
- FIGURE 44. PFIZER: REVENUE SHARE BY GEOGRAPHY, 2017 (%)

## I would like to order

Product name: Immune Checkpoint Inhibitors Market by Type (CTLA-4 Inhibitor, PD-1 Inhibitor, and PD-L1 Inhibitor) and Application (Lung Cancer, Bladder Cancer, Melanoma, Hodgkin Lymphoma, and Others) - Global Opportunity Analysis and Industry Forecast, 2018-2025

Product link: <https://marketpublishers.com/r/IAAB2F7AD7AEN.html>

Price: US\$ 5,370.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

[info@marketpublishers.com](mailto:info@marketpublishers.com)

## Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/IAAB2F7AD7AEN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:  
Last name:  
Email:  
Company:  
Address:  
City:  
Zip code:  
Country:  
Tel:  
Fax:  
Your message:

**\*\*All fields are required**

Customer signature \_\_\_\_\_

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below

and fax the completed form to +44 20 7900 3970